Phase 2 Trial in First-Line Pancreatic Cancer Patients
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Amplia Therapeutics
- AGM - Chief Executive Officers Presentatioin
- Quarterly Activities and Cashflow Reports and Presentation
- Results from Successful Phase 1 Clinical Trial of AMP945
- Amplia and Garvan Enter Into Collaboration Agreement
- AMP945 Improves Survival in Pacnreatic Cancer Model
Later from Amplia Therapeutics
- New Garvan Publication Supports Amplia Phase 2 Design
- Amplia Receives $1.1m R&D Tax Incentive
- Quarterly Activities and Cashflow Reports - Sep 2021 Qtr
- Placement and Underwritten Entitlement Offer to Raise $12.4m
- Entitlement Offer Prospectus
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics